Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

ribociclib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × HER2-positive Advanced Breast Cancer × Clear all
NCT06481956 2024-07-01

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Zhejiang Cancer Hospital

Phase 2 Enrolling by invitation
40 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT04903652 2022-04-07

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed
30 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡